Vol. 44 (3): 429-432, May – June, 2018
DIFFERENCE OF OPINION
Stenio de Cassio Zequi 1, Thiago Camelo Mourao 2, Gustavo Cardoso Guimaraes 1
1 Divisão de Urologia, AC Camargo Cancer Center, Fundação A. Prudente, São Paulo, SP, Brasil; 2 Departamento de Urooncologia, Laparoscopia e Robótica, AC Camargo Cancer Center, Fundação A. Prudente, São Paulo, SP, Brasil
Keywords: High-Intensity Focused Ultrasound Ablation; Prostatic Neoplasms; Radiotherapy
Currently, about one third of all newly diagnosed prostate cancer patients select radiotherapy or brachytherapy (BT) as their primary treatment (1). Primary external beam radiation therapy (EBRT) in localized prostate cancer has a risk of biochemical recurrence about 30-60% (1, 2). The most widely utilized criteria for EBRT biochemical relapse is the Phoenix definition (2006). It is established as a PSA elevation of ≥ 2 ng/mL above the nadir PSA (3).There are a variety of treatment options, like watchful waiting, androgen deprivation therapy (ADT) and local salvage therapies. None of them are accepted as gold standard salvage treatments. Another important point is that recurrences are associated with an increased risk of death, metastases and local complications, such as ureteral obstruction, hematuria and pelvic pain (1).